Ruxolitinib-loaded poly-ɛ-caprolactone (PCL) nanoparticles inhibit JAK2/STAT5 signaling in BT474 breast cancer cells by downregulating Bcl-2 and Mcl-1
- 22 July 2024
- journal article
- research article
- Published by Springer Nature in Molecular Biology Reports
- Vol. 51 (1) , 1-13
Abstract
Background JAK/STAT signaling plays an important role in regulating cell proliferation. Reducing proliferation and inducing cell death with gene-specific inhibitors such as ruxolitinib, Receptor tyrosine kinases (RTK) inhibitor targeting JAK1/2, are therapeutic approaches. The use of nanoparticles can reduce the toxicity and side effects of drugs, as they act directly on cancer cells and can selectively increase drug accumulation in tumor cells. Poly-ɛ-caprolactone (PCL) is a polymer that is frequently used in drug development. In this study, Rux-PCL-NPs were synthesized to increase the effectiveness of ruxolitinib. In addition, this study aimed to determine the effect of Rux-PCL-NPs on JAK/STAT signaling and apoptotic cell death. Methods and results Rux-PCL-NPs were synthesized by nanoprecipitation. The Rux-PCL-NPs had a spherical and mean particle size of 219 ± 88.66 nm and a zeta potential of 0.471 ± 0.453 mV. In vitro cytotoxicity and antiproliferative effects were determined by MTT and soft agar colony formation assays, respectively. The effects of ruxolitinib, PCL-NPs, and Rux-PCL-NPs on apoptosis and the JAK/STAT pathway in cells were examined by western blot analysis. PCL-NPs did not have a toxic effect on the cells. The IC50 value of Rux-PCL-NPs was decreased 50-fold compared to that of ruxolitinib. Rux-PCL-NPs promoted cell death by downregulating JAK2 and STAT5, thereby inhibiting the JAK/STAT pathway. Conclusions Our results revealed that Rux-PCL-NPs, which increased the efficacy of ruxolitinib, regulated apoptosis and the JAK2/STAT5 pathway.Keywords
All Related Versions
Funding Information
- Bilecik Seyh Edebali University (2018-02. BŞEÜ.01-01, 2018-02. BŞEÜ.01-01)
This publication has 41 references indexed in Scilit:
- Combined treatment with ruxolitinib and MK-2206 inhibits the JAK2/STAT5 and PI3K/AKT pathways via apoptosis in MDA-MB-231 breast cancer cell lineMolecular Biology Reports, 2022
- Targeting apoptotic caspases in cancerBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2020
- Aromatase inhibitors: Role in postmenopausal breast cancerArchiv der Pharmazie, 2020
- Intratumoral administration of carboplatin bearing poly (ε-caprolactone) nanoparticles amalgamated with in situ gel tendered augmented drug delivery, cytotoxicity, and apoptosis in melanoma tumorColloids and Surfaces B: Biointerfaces, 2018
- A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancerBiomedicine & Pharmacotherapy, 2017
- Fabrication, characterization, in vitro drug release and glucose uptake activity of 14-deoxy, 11, 12-didehydroandrographolide loaded polycaprolactone nanoparticlesAsian Journal of Pharmaceutical Sciences, 2017
- Encapsulation of alendronate sodium by nanoprecipitation and double emulsion: From preparation to in vitro studiesIndustrial Crops and Products, 2015
- Core–shell hybrid nanocapsules for oral delivery of camptothecin: formulation development, in vitro and in vivo evaluationJournal of Nanoparticle Research, 2015
- Paclitaxel-loaded PCL–TPGS nanoparticles: In vitro and in vivo performance compared with Abraxane®Colloids and Surfaces B: Biointerfaces, 2014
- Poly-ϵ-caprolactone microspheres and nanospheres: an overviewInternational Journal of Pharmaceutics, 2004